Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Epidemiological changes of acute/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997-2015): a prospective cohort study.

Nicolás D, Ambrosioni J, de Lazzari E, Suarez A, Manzardo C, Agüero F, Mosquera MM, Costa J, Ligero C, Marcos MÁ, Sánchez-Palomino S, Fernández E, Plana M, Yerly S, Gatell JM, Miró JM; Hospital Clinic Acute/Recent HIV Study Group.

Clin Microbiol Infect. 2019 Jul;25(7):878-884. doi: 10.1016/j.cmi.2018.10.021. Epub 2018 Nov 22.

PMID:
30472421
2.

Syphilis Maligna: A Presentation to Bear in Mind.

Fustà-Novell X, Morgado-Carrasco D, Barreiro-Capurro A, Manzardo C, Alsina-Gibert M; Miembros del Grupo de Trabajo de Infecciones de Transmisión Sexual del Hospital Clínic de Barcelona; Miembros del Grupo de Trabajo de Infecciones de Transmisión Sexual del Hospital Clínic de Barcelona.

Actas Dermosifiliogr. 2019 Apr;110(3):232-237. doi: 10.1016/j.ad.2018.02.024. Epub 2018 Aug 8. English, Spanish.

PMID:
30098705
3.

Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.

Manzardo C, Londoño MC, Castells L, Testillano M, Luis Montero J, Peñafiel J, Subirana M, Moreno A, Aguilera V, Luisa González-Diéguez M, Calvo-Pulido J, Xiol X, Salcedo M, Cuervas-Mons V, Manuel Sousa J, Suarez F, Serrano T, Ignacio Herrero J, Jiménez M, Fernandez JR, Giménez C, Del Campo S, Esteban-Mur JI, Crespo G, Moreno A, de la Rosa G, Rimola A, Miro JM; and the FIPSE LT-HIV investigators.

Am J Transplant. 2018 Oct;18(10):2513-2522. doi: 10.1111/ajt.14996. Epub 2018 Aug 13. Erratum in: Am J Transplant. 2019 Feb;19(2):614.

PMID:
29963780
4.

Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy.

Cristelli MP, Trullàs JC, Cofán F, Rico N, Manzardo C, Ambrosioni J, Bedini JL, Moreno A, Diekmann F, Miro JM; CKD-H. Clinical Investigators.

Braz J Infect Dis. 2018 May - Jun;22(3):193-201. doi: 10.1016/j.bjid.2018.05.001. Epub 2018 May 18.

5.

Sexual acquisition of HIV infection after solid organ transplantation: Late presentation and potentially fatal complications.

Cristelli MP, Mazolin MA, Manzardo C, Ribeiro MSJ, Cofán F, Santos DWC, Castel MA, Tedesco-Silva H, Moreno A, Diekman F, Miro JM, Medina-Pestana JO.

Transpl Infect Dis. 2018 Aug;20(4):e12894. doi: 10.1111/tid.12894. Epub 2018 Apr 17.

PMID:
29603514
6.

Neurological involvement in patients with acute/recent HIV-1 infection. A case-control study.

Ambrosioni J, Artigues F, Nicolás D, Peñafiel J, Agüero F, Manzardo C, Mar Mosquera M, Sánchez-Palomino S, De Lazzari E, Marcos MA, Plana M, Miró JM; Hospital Clinic PHI Investigators.

J Neurovirol. 2017 Oct;23(5):679-685. doi: 10.1007/s13365-017-0548-6. Epub 2017 Jul 17.

PMID:
28718069
7.

Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3-year retrospective cohort study.

Cristelli MP, Cofán F, Tedesco-Silva H, Trullàs JC, Santos DWCL, Manzardo C, Agüero F, Moreno A, Oppenheimer F, Diekmann F, Medina-Pestana JO, Miro JM; Sao Paulo-Barcelona Renal Transplant in HIV Investigators.

Transpl Infect Dis. 2017 Aug;19(4). doi: 10.1111/tid.12724. Epub 2017 Jun 26.

PMID:
28508573
8.

Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study.

Cillóniz C, Torres A, Manzardo C, Gabarrús A, Ambrosioni J, Salazar A, García F, Ceccato A, Mensa J, de la Bella Casa JP, Moreno A, Miró JM.

Chest. 2017 Aug;152(2):295-303. doi: 10.1016/j.chest.2017.03.007. Epub 2017 Mar 14.

PMID:
28302496
9.

Human immunodeficiency virus-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study.

Agüero F, Forner A, Valdivieso A, Blanes M, Barcena R, Manzardo C, Rafecas A, Castells L, Abradelo M, Barrera-Baena P, González-Diéguez L, Salcedo M, Serrano T, Jiménez-Pérez M, Herrero JI, Gastaca M, Aguilera V, Fabregat J, Del Campo S, Bilbao I, Romero CJ, Moreno A, Rimola A, Miro JM; FIPSE Investigators.

Liver Transpl. 2017 May;23(5):645-651. doi: 10.1002/lt.24741.

10.

Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis.

Cristelli MP, Cofán F, Rico N, Trullàs JC, Manzardo C, Agüero F, Bedini JL, Moreno A, Oppenheimer F, Miro JM; CKD-H. Clinic Investigators.

BMC Nephrol. 2017 Feb 10;18(1):58. doi: 10.1186/s12882-017-0470-4.

11.

Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial.

Nicolás D, Ambrosioni J, Sued O, Brunet M, López-Diéguez M, Manzardo C, Agüero F, Tuset M, Plana M, Guardo AC, Mosquera MM, Muñoz-Fernández MÁ, Caballero M, Marcos MÁ, Gatell JM, de Lazzari E, Gallart T, Miró JM.

J Antimicrob Chemother. 2017 Mar 1;72(3):829-836. doi: 10.1093/jac/dkw462.

PMID:
27999018
12.

Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection.

Ambrosioni J, Nicolás D, Manzardo C, Agüero F, Blanco JL, Mosquera MM, Peñafiel J, Gatell JM, Marcos MA, Miró JM.

J Antimicrob Chemother. 2017 Jan;72(1):205-209. Epub 2016 Sep 13.

PMID:
27624569
13.

IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.

Londoño MC, Manzardo C, Rimola A, Ruiz P, Costa J, Forner A, Ambrosioni J, Agüero F, Laguno M, Lligoña A, Moreno A, Miró JM.

J Antimicrob Chemother. 2016 Nov;71(11):3195-3201. Epub 2016 Jul 7.

PMID:
27402009
14.

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.

Nicolás D, Esteve A, Cuadros A, Campbell CNJ, Tural C, Podzamczer D, Murillas J, Homar F, Segura F, Force L, Vilaró J, Masabeu À, Garcia I, Mercadal J, Montoliu A, Ferrer E, Riera M, Cifuentes C, Ambrosioni J, Navarro G, Manzardo C, Clotet B, Gatell JM, Casabona J, Miró JM; PISCIS Cohort Study Investigators, Murillas J, Manzardo C, Masabeu A, Mercadal J, Cifuentes C, Dalmau D, Domingo P, Falcó V, Curran A, Agustí C, Montoliu A, Pérez I, Curto J, Gargoulas F, Gómez A, Rubia JC, Zamora L, Blanco JL, Garcia-Alcaide F, Martínez E, Mallolas J, Llibre JM, Sirera G, Romeu J, Jou A, Negredo E, Saumoy M, Imaz A, Bolao F, Cabellos C, Peña C, DiYacovo S, Van Den Eynde E, Sala M, Cervantes M, Amengual MJ, Navarro M, Segura V, Barrufet P, Molina J, Alvaro M, Payeras T, Gracia Mateo M, Fernández J.

Clin Infect Dis. 2016 Jun 15;62(12):1578-1585. doi: 10.1093/cid/ciw157. Epub 2016 Apr 28.

PMID:
27126346
15.

A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; MARAVIPEP Study Group.

J Antimicrob Chemother. 2016 Jul;71(7):1982-6. doi: 10.1093/jac/dkw048. Epub 2016 Mar 18.

PMID:
26994091
16.

A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; RALPEP Study Group.

J Antimicrob Chemother. 2016 Jul;71(7):1987-93. doi: 10.1093/jac/dkw049. Epub 2016 Mar 18.

PMID:
26994089
17.

Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.

Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C, Ambrosioni J, Schultz A, Meyerhans A, Mascola JR, Gatell JM, Alcami J, Miro JM, Yuste E.

J Virol. 2016 May 12;90(11):5231-5245. doi: 10.1128/JVI.00049-16. Print 2016 Jun 1.

18.

Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient.

Ambrosioni J, Coll S, Manzardo C, Nicolás D, Agüero F, Blanco JL, Tuset M, Brunet M, Gatell JM, Miró JM.

J Antimicrob Chemother. 2016 Apr;71(4):1125-7. doi: 10.1093/jac/dkv449. Epub 2016 Jan 10. No abstract available.

PMID:
26755498
19.

Pregnancy in a renal transplant recipient with HIV-1 infection: a case report.

Agüero F, Cofan F, Fortuny C, Lopez M, Manzardo C, Lonca M, Oppenheimer F, Moreno A, Campistol JM, Miro JM.

Antivir Ther. 2016;21(3):267-71. doi: 10.3851/IMP3013. Epub 2015 Nov 18.

PMID:
26576517
20.

Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons.

Ryom L, Boesecke C, Gisler V, Manzardo C, Rockstroh JK, Puoti M, Furrer H, Miro JM, Gatell JM, Pozniak A, Behrens G, Battegay M, Lundgren JD; EACS Governing Board.

HIV Med. 2016 Feb;17(2):83-8. doi: 10.1111/hiv.12322. Epub 2015 Nov 8.

21.

An Update on Heart Transplantation in Human Immunodeficiency Virus-Infected Patients.

Agüero F, Castel MA, Cocchi S, Moreno A, Mestres CA, Cervera C, Pérez-Villa F, Tuset M, Cartañà R, Manzardo C, Guaraldi G, Gatell JM, Miró JM.

Am J Transplant. 2016 Jan;16(1):21-8. doi: 10.1111/ajt.13496. Epub 2015 Nov 2. Review.

22.

Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma.

Agüero F, Forner A, Manzardo C, Valdivieso A, Blanes M, Barcena R, Rafecas A, Castells L, Abradelo M, Torre-Cisneros J, Gonzalez-Dieguez L, Salcedo M, Serrano T, Jimenez-Perez M, Herrero JI, Gastaca M, Aguilera V, Fabregat J, Del Campo S, Bilbao I, Romero CJ, Moreno A, Rimola A, Miro JM; FIPSE Investigators.

Hepatology. 2016 Feb;63(2):488-98. doi: 10.1002/hep.28321. Epub 2016 Jan 4.

PMID:
26516761
23.

Epidemiology of infections by HIV, Syphilis, Gonorrhea and Lymphogranuloma Venereum in Barcelona City: a population-based incidence study.

Martí-Pastor M, García de Olalla P, Barberá MJ, Manzardo C, Ocaña I, Knobel H, Gurguí M, Humet V, Vall M, Ribera E, Villar J, Martín G, Sambeat MA, Marco A, Vives A, Alsina M, Miró JM, Caylà JA; HIV Surveillance Group.

BMC Public Health. 2015 Oct 5;15:1015. doi: 10.1186/s12889-015-2344-7.

24.

Liver Retransplantation in Patients With HIV-1 Infection: An International Multicenter Cohort Study.

Agüero F, Rimola A, Stock P, Grossi P, Rockstroh JK, Agarwal K, Garzoni C, Barcan LA, Maltez F, Manzardo C, Mari M, Ragni MV, Anadol E, Di Benedetto F, Nishida S, Gastaca M, Miró JM; FIPSE/NIH HIVTR/NEAT023 Investigators.

Am J Transplant. 2016 Feb;16(2):679-87. doi: 10.1111/ajt.13461. Epub 2015 Sep 28.

25.

Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease.

Casadellà M, Manzardo C, Noguera-Julian M, Ferrer E, Domingo P, Pérez-Álvarez S, Podzamczer D, Plana M, Clotet B, Gatell JM, Miró JM, Paredes R; ADVANZ and ADVANZ-3 Investigators.

AIDS. 2015 Jul 31;29(12):1493-504. doi: 10.1097/QAD.0000000000000748.

PMID:
26244389
26.

Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.

Sued O, Ambrosioni J, Nicolás D, Manzardo C, Agüero F, Claramonte X, Plana M, Tuset M, Pumarola T, Gallart T, Gatell JM, Miró JM.

PLoS One. 2015 Jul 17;10(7):e0131651. doi: 10.1371/journal.pone.0131651. eCollection 2015.

27.

Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4.

Nicolás D, Ambrosioni J, Paredes R, Marcos MÁ, Manzardo C, Moreno A, Miró JM.

Expert Rev Anti Infect Ther. 2015 Aug;13(8):947-63. doi: 10.1586/14787210.2015.1056157. Epub 2015 Jun 25. Review.

PMID:
26112187
28.

Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012).

Ambrosioni J, Sued O, Nicolas D, Parera M, López-Diéguez M, Romero A, Agüero F, Marcos MÁ, Manzardo C, Zamora L, Gómez-Carrillo M, Gatell JM, Pumarola T, Miró JM.

PLoS One. 2015 Jun 3;10(6):e0125837. doi: 10.1371/journal.pone.0125837. eCollection 2015.

29.

Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review.

Manzardo C, Guardo AC, Letang E, Plana M, Gatell JM, Miro JM.

Expert Rev Anti Infect Ther. 2015 Jun;13(6):751-67. doi: 10.1586/14787210.2015.1029917. Epub 2015 Apr 10. Review.

PMID:
25860288
30.

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).

Miro JM, Manzardo C, Ferrer E, Loncà M, Guardo AC, Podzamczer D, Domingo P, Curran A, Clotet B, Cruceta A, Lozano F, Pérez I, Plana M, Gatell JM; Advanz-3 Study Group.

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):206-15. doi: 10.1097/QAI.0000000000000567.

PMID:
25831464
31.

Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.

Castells L, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, Rodriguez M, Bernal C, Suarez F, Antela A, Olivares S, Del Campo S, Laguno M, Fernandez JR, de la Rosa G, Agüero F, Perez I, González-García J, Esteban-Mur JI, Miro JM; FIPSE LT-HIV Investigators.

J Hepatol. 2015 Jan;62(1):92-100. doi: 10.1016/j.jhep.2014.07.034. Epub 2014 Aug 13. Erratum in: J Hepatol. 2016 Mar;64(3):757.

PMID:
25127748
32.

Evaluation of an antibody avidity index method for detecting recent human immunodeficiency virus type 1 infection using an automated chemiluminescence immunoassay.

Fernández G, Manzardo C, Montoliu A, Campbell C, Fernández G, Casabona J, Miró JM, Matas L, Rivaya B, González V.

Enferm Infecc Microbiol Clin. 2015 Apr;33(4):238-42. doi: 10.1016/j.eimc.2014.04.014. Epub 2014 Jul 22.

PMID:
25060663
33.

[Severe or life-threatening interactions between antiretrovirals and non-HIV drugs].

Manzardo C, Tuset M, Miró JM, Gatell JM.

Enferm Infecc Microbiol Clin. 2015 Aug-Sep;33(7):e15-30. doi: 10.1016/j.eimc.2014.02.020. Epub 2014 Jun 7. Review. Spanish.

PMID:
24913990
34.

Update on antiretroviral treatment during primary HIV infection.

Ambrosioni J, Nicolas D, Sued O, Agüero F, Manzardo C, Miro JM.

Expert Rev Anti Infect Ther. 2014 Jul;12(7):793-807. doi: 10.1586/14787210.2014.913981. Epub 2014 May 7. Review.

PMID:
24803105
35.

Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients.

Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, Saag MS, Manzardo C, Grabar S, Bruyand M, Moore D, Mocroft A, Sterling TR, D'Arminio Monforte A, Hernando V, Teira R, Guest J, Cavassini M, Crane HM, Sterne JA; Antiretroviral Therapy Cohort Collaboration.

Clin Infect Dis. 2014 Jul 15;59(2):287-97. doi: 10.1093/cid/ciu261. Epub 2014 Apr 24.

36.

HIV treatment outcomes in Europe and North America: what can we learn from the differences?

Ambrosioni J, Nicolas D, Agüero F, Manzardo C, Miro JM.

Expert Rev Anti Infect Ther. 2014 May;12(5):523-6. doi: 10.1586/14787210.2014.906900. Epub 2014 Apr 2.

PMID:
24694073
37.
38.

Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.

Kawana-Tachikawa A, Llibre JM, Bravo I, Escrig R, Mothe B, Puig J, Puertas MC, Martinez-Picado J, Blanco J, Manzardo C, Miro JM, Iwamoto A, Pozniak AL, Gatell JM, Clotet B, Brander C; MARAVIBOOST Investigators.

PLoS One. 2014 Jan 27;9(1):e87334. doi: 10.1371/journal.pone.0087334. eCollection 2014.

39.

Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.

Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J; MaraviBoost Collaborative Group.

AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066.

PMID:
24185044
40.

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.

Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Gomez Sirvent JL, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC).

AIDS. 2013 Mar 13;27(5):803-13. doi: 10.1097/QAD.0b013e32835cb997. Erratum in: AIDS. 2014 Jul 31;28(12):1853.

PMID:
23719350
41.

Community-associated methicillin-resistant Staphylococcus aureus infections in HIV-infected patients in Spain.

Imaz A, Cobos-Trigueros N, Falcó V, Dominguez MA, Manzardo C, Pujol M, Curto J, Bartolomé R, Soriano A, Podzamczer D.

J Infect. 2013 Feb;66(2):199-201. doi: 10.1016/j.jinf.2012.10.013. Epub 2012 Oct 13. No abstract available.

PMID:
23072792
42.

Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort.

Manzardo C, Esteve A, Ortega N, Podzamczer D, Murillas J, Segura F, Force L, Tural C, Vilaró J, Masabeu A, Garcia I, Guadarrama M, Ferrer E, Riera M, Navarro G, Clotet B, Gatell JM, Casabona J, Miró JM; PISCIS Investigators.

Clin Microbiol Infect. 2013 Jul;19(7):646-53. doi: 10.1111/j.1469-0691.2012.03991.x. Epub 2012 Sep 12.

43.

Renal dysfunction in the setting of HIV/AIDS.

Miro JM, Cofan F, Trullas JC, Manzardo C, Cervera C, Tuset M, Oppenheimer F, Brunet M, Moreno A, Campistol JM, Gatell JM.

Curr HIV/AIDS Rep. 2012 Sep;9(3):187-99. doi: 10.1007/s11904-012-0125-9. Review.

PMID:
22706955
44.

Liver retransplantation in HIV-infected patients: a prospective cohort study.

Gastaca M, Aguero F, Rimola A, Montejo M, Miralles P, Lozano R, Castells L, Abradelo M, Mata Mde L, San Juan Rodríguez F, Cordero E, Campo Sd, Manzardo C, de Urbina JO, Pérez I, Rosa Gde L, Miro JM; FIPSE OLT-HIV investigators.

Am J Transplant. 2012 Sep;12(9):2465-76. doi: 10.1111/j.1600-6143.2012.04142.x. Epub 2012 Jun 15.

45.

[Clinical management of acute and chronic human immunodeficiency virus infection before starting antiretroviral treatment].

Miró JM, Manzardo C, Zamora L, Pumarola T, Herreras Z, Gallart T, Gatell JM.

Enferm Infecc Microbiol Clin. 2011 Dec;29(10):759-72. doi: 10.1016/j.eimc.2011.10.009. Epub 2011 Nov 10. Review. Spanish.

PMID:
22078726
46.

Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis.

Miro JM, Manzardo C, Mussini C, Johnson M, d'Arminio Monforte A, Antinori A, Gill MJ, Sighinolfi L, Uberti-Foppa C, Borghi V, Sabin C; Late Presenters Investigators.

PLoS One. 2011;6(10):e26009. doi: 10.1371/journal.pone.0026009. Epub 2011 Oct 17.

47.

Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009.

de Olalla PG, Manzardo C, Sambeat MA, Ocaña I, Knobel H, Humet V, Domingo P, Ribera E, Guelar A, Marco A, Belza MJ, Miró JM, Caylà JA; HIV Surveillance Group.

AIDS Res Ther. 2011 Jul 6;8(1):22. doi: 10.1186/1742-6405-8-22.

48.

Renal transplantation in HIV-infected patients: 2010 update.

Trullas JC, Cofan F, Tuset M, Ricart MJ, Brunet M, Cervera C, Manzardo C, López-Dieguez M, Oppenheimer F, Moreno A, Campistol JM, Miro JM.

Kidney Int. 2011 Apr;79(8):825-42. doi: 10.1038/ki.2010.545. Epub 2011 Jan 19. Review.

49.

Simultaneous pancreas-kidney transplantation in HIV-infected patients: a case report and literature review.

Miro JM, Ricart MJ, Trullas JC, Cofan F, Cervera C, Brunet M, Tuset M, Manzardo C, Oppenheimer F, Moreno A.

Transplant Proc. 2010 Nov;42(9):3887-91. doi: 10.1016/j.transproceed.2010.09.003. Review.

PMID:
21094878
50.

Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.

Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Loncá M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM; Advanz Study Group.

AIDS Res Hum Retroviruses. 2010 Jul;26(7):747-57. doi: 10.1089/aid.2009.0105.

PMID:
20624069

Supplemental Content

Loading ...
Support Center